NASDAQ:BVXV

BiondVax Pharmaceuticals Competitors

$3.09
+0.07 (+2.32 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.00
Now: $3.09
$3.18
50-Day Range
$3.02
MA: $3.91
$4.41
52-Week Range
$2.35
Now: $3.09
$62.00
Volume101,144 shs
Average Volume939,693 shs
Market Capitalization$35.08 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41

Competitors

BiondVax Pharmaceuticals (NASDAQ:BVXV) Vs. DYAI, PSTI, AYLA, AZYO, TCON, and GNCA

Should you be buying BVXV stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to BiondVax Pharmaceuticals, including Dyadic International (DYAI), Pluristem Therapeutics (PSTI), Ayala Pharmaceuticals (AYLA), Aziyo Biologics (AZYO), TRACON Pharmaceuticals (TCON), and Genocea Biosciences (GNCA).

BiondVax Pharmaceuticals (NASDAQ:BVXV) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Risk and Volatility

BiondVax Pharmaceuticals has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500.

Earnings and Valuation

This table compares BiondVax Pharmaceuticals and Dyadic International's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiondVax PharmaceuticalsN/AN/A$-31,600,000.00($3.60)-0.86
Dyadic International$1.68 million82.17$-8,310,000.00($0.31)-16.16

Dyadic International has higher revenue and earnings than BiondVax Pharmaceuticals. Dyadic International is trading at a lower price-to-earnings ratio than BiondVax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

4.0% of BiondVax Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.2% of Dyadic International shares are owned by institutional investors. 6.0% of BiondVax Pharmaceuticals shares are owned by insiders. Comparatively, 23.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BiondVax Pharmaceuticals and Dyadic International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BiondVax Pharmaceuticals0000N/A
Dyadic International00103.00

Dyadic International has a consensus price target of $11.00, indicating a potential upside of 119.56%. Given Dyadic International's higher probable upside, analysts plainly believe Dyadic International is more favorable than BiondVax Pharmaceuticals.

Profitability

This table compares BiondVax Pharmaceuticals and Dyadic International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiondVax PharmaceuticalsN/AN/A-135.18%
Dyadic International-539.34%-27.54%-26.33%

Summary

Dyadic International beats BiondVax Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

BiondVax Pharmaceuticals (NASDAQ:BVXV) and Pluristem Therapeutics (NASDAQ:PSTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Risk and Volatility

BiondVax Pharmaceuticals has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Comparatively, Pluristem Therapeutics has a beta of 2.53, meaning that its share price is 153% more volatile than the S&P 500.

Earnings and Valuation

This table compares BiondVax Pharmaceuticals and Pluristem Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiondVax PharmaceuticalsN/AN/A$-31,600,000.00($3.60)-0.86
Pluristem Therapeutics$20,000.006,887.58$-29,150,000.00N/AN/A

Pluristem Therapeutics has higher revenue and earnings than BiondVax Pharmaceuticals.

Insider & Institutional Ownership

4.0% of BiondVax Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.0% of Pluristem Therapeutics shares are owned by institutional investors. 6.0% of BiondVax Pharmaceuticals shares are owned by insiders. Comparatively, 4.9% of Pluristem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BiondVax Pharmaceuticals and Pluristem Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BiondVax Pharmaceuticals0000N/A
Pluristem Therapeutics01302.75

Pluristem Therapeutics has a consensus price target of $9.75, indicating a potential upside of 124.65%. Given Pluristem Therapeutics' higher probable upside, analysts plainly believe Pluristem Therapeutics is more favorable than BiondVax Pharmaceuticals.

Profitability

This table compares BiondVax Pharmaceuticals and Pluristem Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiondVax PharmaceuticalsN/AN/A-135.18%
Pluristem TherapeuticsN/A-86.51%-68.23%

Summary

Pluristem Therapeutics beats BiondVax Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

BiondVax Pharmaceuticals (NASDAQ:BVXV) and Ayala Pharmaceuticals (NASDAQ:AYLA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Earnings and Valuation

This table compares BiondVax Pharmaceuticals and Ayala Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiondVax PharmaceuticalsN/AN/A$-31,600,000.00($3.60)-0.86
Ayala Pharmaceuticals$2.33 million59.07$-17,790,000.00N/AN/A

Ayala Pharmaceuticals has higher revenue and earnings than BiondVax Pharmaceuticals.

Insider & Institutional Ownership

4.0% of BiondVax Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.8% of Ayala Pharmaceuticals shares are owned by institutional investors. 6.0% of BiondVax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BiondVax Pharmaceuticals and Ayala Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BiondVax Pharmaceuticals0000N/A
Ayala Pharmaceuticals01502.83

Ayala Pharmaceuticals has a consensus price target of $24.20, indicating a potential upside of 131.58%. Given Ayala Pharmaceuticals' higher probable upside, analysts plainly believe Ayala Pharmaceuticals is more favorable than BiondVax Pharmaceuticals.

Profitability

This table compares BiondVax Pharmaceuticals and Ayala Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiondVax PharmaceuticalsN/AN/A-135.18%
Ayala Pharmaceuticals-850.81%-625.24%-70.31%

Summary

Ayala Pharmaceuticals beats BiondVax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

BiondVax Pharmaceuticals (NASDAQ:BVXV) and Aziyo Biologics (NASDAQ:AZYO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Earnings and Valuation

This table compares BiondVax Pharmaceuticals and Aziyo Biologics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiondVax PharmaceuticalsN/AN/A$-31,600,000.00($3.60)-0.86
Aziyo BiologicsN/AN/AN/AN/AN/A

Insider & Institutional Ownership

4.0% of BiondVax Pharmaceuticals shares are owned by institutional investors. 6.0% of BiondVax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BiondVax Pharmaceuticals and Aziyo Biologics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BiondVax Pharmaceuticals0000N/A
Aziyo Biologics00403.00

Aziyo Biologics has a consensus price target of $20.00, indicating a potential upside of 55.04%. Given Aziyo Biologics' higher probable upside, analysts plainly believe Aziyo Biologics is more favorable than BiondVax Pharmaceuticals.

Profitability

This table compares BiondVax Pharmaceuticals and Aziyo Biologics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiondVax PharmaceuticalsN/AN/A-135.18%
Aziyo BiologicsN/AN/AN/A

Summary

Aziyo Biologics beats BiondVax Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

BiondVax Pharmaceuticals (NASDAQ:BVXV) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Risk and Volatility

BiondVax Pharmaceuticals has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Comparatively, TRACON Pharmaceuticals has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.

Insider & Institutional Ownership

4.0% of BiondVax Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.0% of TRACON Pharmaceuticals shares are owned by institutional investors. 6.0% of BiondVax Pharmaceuticals shares are owned by insiders. Comparatively, 23.3% of TRACON Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for BiondVax Pharmaceuticals and TRACON Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BiondVax Pharmaceuticals0000N/A
TRACON Pharmaceuticals00403.00

TRACON Pharmaceuticals has a consensus price target of $16.6667, indicating a potential upside of 106.78%. Given TRACON Pharmaceuticals' higher probable upside, analysts plainly believe TRACON Pharmaceuticals is more favorable than BiondVax Pharmaceuticals.

Profitability

This table compares BiondVax Pharmaceuticals and TRACON Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BiondVax PharmaceuticalsN/AN/A-135.18%
TRACON PharmaceuticalsN/A-273.66%-84.56%

Earnings and Valuation

This table compares BiondVax Pharmaceuticals and TRACON Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BiondVax PharmaceuticalsN/AN/A$-31,600,000.00($3.60)-0.86
TRACON Pharmaceuticals$3 million41.59$-22,670,000.00($7.47)-1.08

TRACON Pharmaceuticals has higher revenue and earnings than BiondVax Pharmaceuticals. TRACON Pharmaceuticals is trading at a lower price-to-earnings ratio than BiondVax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

TRACON Pharmaceuticals beats BiondVax Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Genocea Biosciences (NASDAQ:GNCA) and BiondVax Pharmaceuticals (NASDAQ:BVXV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility & Risk

Genocea Biosciences has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Comparatively, BiondVax Pharmaceuticals has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500.

Insider & Institutional Ownership

53.8% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 4.0% of BiondVax Pharmaceuticals shares are owned by institutional investors. 2.1% of Genocea Biosciences shares are owned by company insiders. Comparatively, 6.0% of BiondVax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Genocea Biosciences and BiondVax Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genocea Biosciences00303.00
BiondVax Pharmaceuticals0000N/A

Genocea Biosciences currently has a consensus target price of $7.00, indicating a potential upside of 216.74%. Given Genocea Biosciences' higher possible upside, equities analysts clearly believe Genocea Biosciences is more favorable than BiondVax Pharmaceuticals.

Profitability

This table compares Genocea Biosciences and BiondVax Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Genocea BiosciencesN/A-237.31%-62.30%
BiondVax PharmaceuticalsN/AN/A-135.18%

Earnings & Valuation

This table compares Genocea Biosciences and BiondVax Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/A$-38,950,000.00($2.09)-1.06
BiondVax PharmaceuticalsN/AN/A$-31,600,000.00($3.60)-0.86

Genocea Biosciences is trading at a lower price-to-earnings ratio than BiondVax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


BiondVax Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Dyadic International logo
DYAI
Dyadic International
1.3$5.01+1.6%$138.05 million$1.68 million-14.74Increase in Short Interest
Gap Down
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.34+0.0%$137.75 million$20,000.000.00News Coverage
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.45+0.5%$137.63 million$2.33 million0.00Gap Down
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$12.90+0.6%$131.92 millionN/A0.00Gap Down
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$8.06+3.1%$124.76 million$3 million-2.59Analyst Upgrade
News Coverage
Gap Down
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.21+4.5%$118.28 millionN/A-1.52Analyst Report
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.13+2.6%$111.81 millionN/A-2.98
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.07+2.7%$111.63 million$23.05 million-1.81Gap Down
PolarityTE logo
PTE
PolarityTE
1.4$0.88+2.3%$106.45 million$5.65 million-0.53Increase in Short Interest
Gap Down
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.14+1.9%$102.81 million$20.92 million-1.23
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.10+0.5%$100.43 million$140,000.000.00
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$9.34+0.5%$68.49 millionN/A0.00Lockup Expiration
BioCardia logo
BCDA
BioCardia
1.5$3.98+3.5%$65.03 million$710,000.00-2.05Analyst Downgrade
Increase in Short Interest
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.12+1.8%$63.77 millionN/A-0.89
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.77+1.9%$60.36 million$420,000.00-1.42Increase in Short Interest
News Coverage
Organovo logo
ONVO
Organovo
0.7$8.41+3.7%$59.85 million$2.20 million0.00News Coverage
Gap Down
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.87+0.8%$58.16 million$10,000.000.00Gap Down
Brickell Biotech logo
BBI
Brickell Biotech
1.5$0.84+0.0%$56.50 million$7.92 million-0.35News Coverage
Windtree Therapeutics logo
WINT
Windtree Therapeutics
2.3$2.14+1.9%$56.19 million$200,000.00-0.89Decrease in Short Interest
News Coverage
Microbot Medical logo
MBOT
Microbot Medical
1.3$7.55+2.3%$53.67 millionN/A0.00Decrease in Short Interest
Gap Down
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.8$1.10+1.8%$46.48 million$1.45 million-0.39Increase in Short Interest
Gap Up
Acorda Therapeutics logo
ACOR
Acorda Therapeutics
1.4$4.19+6.2%$39.76 million$192.41 million0.76News Coverage
ENTX
Entera Bio
1.2$3.00+10.0%$34.29 million$240,000.00-4.41News Coverage
Seneca Biopharma logo
SNCA
Seneca Biopharma
0.5$1.39+2.2%$24.04 million$10,000.000.00Increase in Short Interest
Titan Pharmaceuticals logo
TTNP
Titan Pharmaceuticals
1.2$2.29+0.0%$22.59 million$3.61 million-0.31News Coverage
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.